Core Viewpoint - The company demonstrates strong confidence in its business operations, particularly in the fields of narcotic drugs and elderly care services, as discussed during a recent offline research meeting with institutional investors. Group 1: Narcotic Drug Development - The company has established a comprehensive product cluster in the narcotic pain relief sector, with a focus on the oxycodone series, which includes both raw materials and formulations [2] - The company is the only domestic pharmaceutical enterprise with an integrated advantage in oxycodone raw material and formulation, supported by 100% self-supply of raw materials and strong cost control [2] - The company disclosed that its oxycodone sustained-release tablets are in the registration review stage, with expected approvals in Q4 2026 for the 40mg version and Q3 2027 for the 10mg version [3] - The company emphasizes a unique self-operated model for promoting oxycodone sustained-release tablets, focusing on academic-driven strategies and digital penetration to enhance market coverage [3] - In the ADHD medication sector, the company utilizes a resin-controlled release microsphere technology to improve dosing precision and enhance efficacy and safety for children [3] Group 2: Elderly Care Business Optimization - The company has made significant progress in optimizing its elderly care business model, focusing on cost reduction and efficiency improvements [4] - The Nalan Garden elderly care project has implemented a three-dimensional pricing model to enhance profit contributions per bed while improving service quality and client structure [4] - The company plans to maintain high occupancy rates in community elderly care services while refining management and service quality [4] - The Taihe Ruiyuan project will launch a "trial stay experience" initiative to address the challenges of high turnover rates among elderly residents, enhancing brand promotion and occupancy conversion [5] - The company aims to adapt to changes in centralized procurement policies by focusing on differentiated products and comprehensive value competition strategies [5]